Involvement_NN
of_IN
phospholipase_NN
D_NN
in_IN
the_DT
activation_NN
of_IN
transcription_NN
factor_NN
AP-1_NN
in_IN
human_JJ
T_NN
lymphoid_JJ
Jurkat_NN
cells_NNS
._.

The_DT
induction_NN
of_IN
the_DT
AP-1_NN
transcription_NN
factor_NN
has_VBZ
been_VBN
ascribed_VBN
to_TO
the_DT
early_JJ
events_NNS
leading_VBG
to_TO
T_NN
lymphocyte_NN
activation_NN
._.

We_PRP
have_VBP
examined_VBN
the_DT
possibility_NN
that_IN
stimulation_NN
of_IN
phospholipase_NN
D_NN
-LRB-_-LRB-
PLD_NN
-RRB-_-RRB-
may_MD
regulate_VB
activation_NN
of_IN
transcription_NN
factor_NN
AP-1_NN
in_IN
human_JJ
T_NN
cells_NNS
by_IN
transfecting_VBG
human_JJ
T_NN
lymphocyte_NN
Jurkat_NN
cells_NNS
with_IN
a_DT
plasmid_NN
containing_VBG
an_DT
AP-1_NN
enhancer_NN
element_NN
and_CC
a_DT
chloramphenicol_NN
acetyltransferase_NN
reporter_NN
gene_NN
._.

We_PRP
have_VBP
detected_VBN
activatable_JJ
PLD_NN
in_IN
Jurkat_NN
cells_NNS
,_,
and_CC
we_PRP
have_VBP
found_VBN
that_IN
addition_NN
of_IN
phosphatidic_JJ
acid_NN
-LRB-_-LRB-
PA_NN
-RRB-_-RRB-
,_,
the_DT
physiologic_JJ
product_NN
of_IN
PLD_NN
action_NN
on_IN
phospholipids_NNS
,_,
is_VBZ
rapidly_RB
incorporated_VBN
into_IN
Jurkat_NN
cells_NNS
and_CC
leads_VBZ
to_TO
activation_NN
of_IN
transcription_NN
factor_NN
AP-1_NN
._.

Treatment_NN
of_IN
Jurkat_NN
cells_NNS
with_IN
anti-CD3_JJ
mAb_NN
activated_VBD
both_CC
PLD_NN
and_CC
transcription_NN
factor_NN
AP-1_NN
._.

Wortmannin_NN
,_,
an_DT
inhibitor_NN
of_IN
receptor-coupled_JJ
PLD_NN
activation_NN
,_,
blocked_VBD
the_DT
anti-CD3-induced_JJ
increases_NNS
in_IN
both_CC
PLD_NN
activity_NN
and_CC
AP-1_NN
enhancer_NN
activity_NN
._.

We_PRP
found_VBD
a_DT
good_JJ
correlation_NN
in_IN
the_DT
transfected_VBN
cells_NNS
between_IN
PLD_NN
activation_NN
and_CC
induction_NN
of_IN
AP-1_NN
enhancer_NN
activity_NN
under_IN
different_JJ
experimental_JJ
conditions_NNS
._.

Furthermore_RB
,_,
ethanol_NN
,_,
an_DT
inhibitor_NN
of_IN
the_DT
PLD_NN
pathway_NN
,_,
blocked_VBD
the_DT
anti-CD3-stimulated_JJ
AP-1_NN
enhancer_NN
activity_NN
._.

However_RB
,_,
this_DT
anti-CD3-mediated_JJ
response_NN
was_VBD
not_RB
inhibited_VBN
by_IN
neomycin_NN
,_,
an_DT
inhibitor_NN
of_IN
phosphoinositide_NN
hydrolysis_NN
._.

The_DT
increases_NNS
in_IN
AP-1_NN
enhancer_NN
activity_NN
induced_VBN
by_IN
PA_NN
or_CC
anti-CD3_JJ
mAb_NN
were_VBD
efficiently_RB
abrogated_VBN
by_IN
the_DT
presence_NN
of_IN
propranolol_NN
,_,
an_DT
inhibitor_NN
of_IN
PA_NN
phosphohydrolase_NN
and_CC
protein_NN
kinase_NN
C_NN
-LRB-_-LRB-
PKC_NN
-RRB-_-RRB-
._.

Furthermore_RB
,_,
the_DT
PA_NN
-_:
and_CC
the_DT
anti-CD3-induced_JJ
increases_NNS
in_IN
AP-1_NN
enhancer_NN
activity_NN
were_VBD
blocked_VBN
by_IN
the_DT
presence_NN
of_IN
PKC_NN
inhibitors_NNS
or_CC
by_IN
PKC_NN
down-regulation_NN
._.

These_DT
data_NNS
indicate_VBP
that_IN
PLD_NN
stimulation_NN
can_MD
activate_VB
the_DT
transcription_NN
factor_NN
AP-1_NN
in_IN
T_NN
lymphocytes_NNS
,_,
and_CC
suggest_VBP
that_IN
the_DT
induction_NN
of_IN
AP-1_NN
enhancer_NN
factor_NN
activity_NN
by_IN
PA_NN
is_VBZ
mediated_VBN
via_IN
PKC_NN
stimulation_NN
,_,
either_CC
through_IN
a_DT
direct_JJ
activating_VBG
effect_NN
of_IN
PA_NN
or_CC
through_IN
PA-derived_JJ
diacylglycerol_NN
formation_NN
._.

These_DT
data_NNS
also_RB
provide_VBP
evidence_NN
for_IN
a_DT
role_NN
of_IN
PLD-derived_JJ
lipids_NNS
in_IN
the_DT
induction_NN
of_IN
AP-1_NN
enhancer_NN
activity_NN
resulting_VBG
from_IN
stimulation_NN
of_IN
the_DT
TCR\/CD3_JJ
complex_NN
,_,
suggesting_VBG
that_IN
increased_VBN
PLD_NN
activity_NN
can_MD
play_VB
an_DT
important_JJ
role_NN
in_IN
T_NN
lymphocyte_NN
activation_NN
._.

